<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326504</url>
  </required_header>
  <id_info>
    <org_study_id>FBAI</org_study_id>
    <nct_id>NCT04326504</nct_id>
  </id_info>
  <brief_title>Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil</brief_title>
  <acronym>CODE</acronym>
  <official_title>Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil: A Population-based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Bahiana de Infectologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Infectologia Evandro Chagas, Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Infectologia Emilio Ribas, S. Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Medicina Tropical de Manaus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital da Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Referência e Tratamento, CRT, São Paulo, SP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal de Minas gerais, MG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EMESCAN, Vitória, Espírito Santo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Partenon, Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital das Clinicas, Recife</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundação Bahiana de Infectologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Access to antiretroviral therapy (ART) in low-income and middle-income countries has been
      scaled-up effectively over recent years. Recently, the World Health Organization (WHO)
      guidelines changed to recommend the use of Dolutegravir (DTG) combined with two nucleoside
      reverse transcriptase inhibitors (NRTIs), tenofovir and lamivudine, for first-line ART;
      however, there is still a need for further data on the outcomes of DTG-based regimens for
      people with HIV-1.

      This study aims to describe the outcomes of drug-naïve and experienced patients starting a
      dolutegravir (DTG)-based regimen in a large cohort of HIV - infected patients in Brazil and
      compare to outcomes obtained from a retrospective control group of subjects who initiated
      non-DTG-based ART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CODE is a multicenter prospective observational study to describe and quantify the outcomes
      of patients starting DTG-based regimens. We will follow ART-naïve patients starting DTG-based
      regimens (Group 1), patients on stable ART regimens switching to DTG (any reason) (Group 2),
      and ART-experienced patients switching to DTG-containing regimens due to virological failure
      (Group 3). In addition, for comparison purposes, we will collect data on patients who started
      a non-DTG containing regimen (Group 4) in the period for 2014-2016 and did not switch to
      DTG-based regimens (Figure 1). Enrolled patients will be followed for 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>therapy discontinuation due to any event for patients starting ART</measure>
    <time_frame>36 months</time_frame>
    <description>The key outcomes of interest include treatment discontinuation due to any event as well as specifically due to metabolic and psychiatric events, virologic outcomes (viral suppression at 12 months, failure to ART, and genotypic results of acquired resistance), clinical outcomes (including noted side effects, retention in care, death, weight changes, hyperglycemia, diabetes, lipid changes, AIDS-defining illnesses, and recorded psychiatric and CNS effects), and special outcomes / populations (pregnancy outcomes, IRIS events, changes in HRQoL, viral hepatitis flares, and tuberculosis outcomes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>therapy discontinuation due to any event for pateitns starting ART</measure>
    <time_frame>36 months</time_frame>
    <description>therapy discontinuation due to any event for ART-experienced patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory outcomes</measure>
    <time_frame>36 months</time_frame>
    <description>These clinical outcomes include: all-cause mortality; all AIDS-defining events; all types of cancer; bacterial pneumonia; pulmonary embolism; deep vein thrombosis; new-onset diabetes mellitus (as defined by the ADA criteria);10 coronary artery disease requiring drug treatment; congestive heart failure; peripheral vascular disease; fractures; and solicited adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life for patients switching to DTG-based regimens</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Physical and Mental Components Scores will be measured. HRQoL evaluation will be performed only for patients switching to DTG-based regimens, at the time switch occurs (baseline), and after 6 and 12 months of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV drug resistance</measure>
    <time_frame>36 months</time_frame>
    <description>This outcome will be evaluated by collecting samples of blood prior to starting DTG-based ART. These tests will not be done in real time, and results will not be given to the investigator or participant. Once virological failure is identified, the baseline sample will be used to assess transmitted drug resistance through comparison with current resistance genotypic tests. Key mutations that are associated with viral resistance will be determined using information periodically updated by the International AIDS Society.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of CVD risk</measure>
    <time_frame>36 months</time_frame>
    <description>Assessments will be made of blood lipids, smoking, blood pressure, incidence of diabetes mellitus, use of medication to lower blood pressure and lipids, and the use of aspirin, to assist in the evaluation of cardiovascular risks and benefits of early treatment.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>HIV Infections</condition>
  <condition>Clinical Outcomes</condition>
  <condition>Adverse Drug Event</condition>
  <condition>Effect of Drugs</condition>
  <arm_group>
    <arm_group_label>Patients starting DTG-based regimens</arm_group_label>
    <description>ART-naïve patients, starting cART regimens based on DTG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch cohort</arm_group_label>
    <description>Patients on stable ART regimens switching to DTG (any reason)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy failure</arm_group_label>
    <description>ART-experienced patients switching to DTG-containing regimens due to virological failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-DTG group</arm_group_label>
    <description>Patients who started a non-DTG containing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This will be an observational study, no intervention will be performed</description>
    <arm_group_label>Non-DTG group</arm_group_label>
    <arm_group_label>Patients starting DTG-based regimens</arm_group_label>
    <arm_group_label>Switch cohort</arm_group_label>
    <arm_group_label>Therapy failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CODE is a multicenter prospective observational study to describe and quantify the outcomes
        of patients starting DTG-based regimens. We will follow ART-naïve patients starting
        DTG-based regimens (Group 1), patients on stable ART regimens switching to DTG (any reason)
        (Group 2), and ART-experienced patients switching to DTG-containing regimens due to
        virological failure (Group 3). In addition, for comparison purposes, we will collect data
        on patients who started a non-DTG containing regimen (Group 4) in the period for 2014-2016
        and did not switch to DTG-based regimens (Figure 1).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Signed informed consent.

               -  HIV infection documented by plasma HIV RNA viral load, a rapid HIV test or any
                  licensed ELISA test; and confirmed by another test using a different method,
                  including but not limited to a rapid HIV test, Western Blot, HIV culture, HIV
                  antigen, or HIV pro-viral DNA at any time prior to study entry.

               -  Age ≥ 15 years.

               -  For women of child-bearing potential, willingness to use effective
                  contraceptives.

               -  Starting use of DTG-based regimen, or being initiated on a non-DTG based ART
                  between 2014 - 2016.

        Exclusion Criteria:

          -  • Any previous use of ART (drug-naïve group only).

               -  Current imprisonment, or compulsory detention (involuntary incarceration). For
                  treatment of a psychiatric or physical illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Brites, MD, PhD</last_name>
    <phone>557132838123</phone>
    <email>crbrites@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estela Luz, RN, MPH</last_name>
    <phone>557132838123</phone>
    <email>eluz5@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundação Bahiana de Infectologia/SEI</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.aids.gov.br/pt-br/tags/publicacoes/protocolo-clinico-e-diretrizes-terapeuticas</url>
    <description>12. Ministério da Saúde, Brasil, 2018. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos.</description>
  </link>
  <results_reference>
    <citation>Dutertre M, Cuzin L, Demonchy E, Puglièse P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G; DatʼAIDS Study Group. Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e23-e26. doi: 10.1097/QAI.0000000000001397.</citation>
    <PMID>28418992</PMID>
  </results_reference>
  <results_reference>
    <citation>de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016 Nov 28;30(18):2831-2834.</citation>
    <PMID>27824625</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciccullo A, Baldin G, Cossu MV, Passerini M, Borghetti A, Capetti A, Di Giambenedetto S. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice. AIDS Res Hum Retroviruses. 2020 Jan;36(1):4-5. doi: 10.1089/AID.2019.0147. Epub 2019 Sep 30.</citation>
    <PMID>31476877</PMID>
  </results_reference>
  <results_reference>
    <citation>Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, Günthard H, Bernasconi E, Battegay M; Swiss HIV Cohort Study Group. Adverse events of raltegravir and dolutegravir. AIDS. 2017 Aug 24;31(13):1853-1858. doi: 10.1097/QAD.0000000000001590.</citation>
    <PMID>28692533</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017 Jan;18(1):56-63. doi: 10.1111/hiv.12468. Epub 2016 Nov 10.</citation>
    <PMID>27860104</PMID>
  </results_reference>
  <results_reference>
    <citation>Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531. doi: 10.1097/QAI.0000000000001525.</citation>
    <PMID>28825943</PMID>
  </results_reference>
  <results_reference>
    <citation>Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group . Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239. eCollection 2017 Fall.</citation>
    <PMID>29255735</PMID>
  </results_reference>
  <results_reference>
    <citation>Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.</citation>
    <PMID>30037297</PMID>
  </results_reference>
  <results_reference>
    <citation>American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. doi: 10.2337/dc19-S002. Review.</citation>
    <PMID>30559228</PMID>
  </results_reference>
  <results_reference>
    <citation>Cruz LN, Fleck MP, Oliveira MR, Camey SA, Hoffmann JF, Bagattini AM, Polanczyk CA. Health-related quality of life in Brazil: normative data for the SF-36 in a general population sample in the south of the country. Cien Saude Colet. 2013 Jul;18(7):1911-21.</citation>
    <PMID>23827895</PMID>
  </results_reference>
  <results_reference>
    <citation>Laguardia J, Campos MR, Travassos C, Najar AL, Anjos LA, Vasconcellos MM. Brazilian normative data for the Short Form 36 questionnaire, version 2. Rev Bras Epidemiol. 2013 Dec;16(4):889-97. English, Portuguese.</citation>
    <PMID>24896594</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

